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Summary
Background By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa 
had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who 
have survived EVD. We aimed to use biostatistical modelling to describe the dynamics of Ebola virus RNA load in 
seminal ﬂ uid, including clearance parameters.
Methods In this longitudinal study, we recruited men who had been discharged from three Ebola treatment units in 
Guinea between January and July, 2015. Participants provided samples of seminal ﬂ uid at follow-up every 3–6 weeks, 
which we tested for Ebola virus RNA using quantitative real-time RT-PCR. Representative specimens from eight 
participants were then inoculated into immunodeﬁ cient mice to test for infectivity. We used a linear mixed-eﬀ ect 
model to analyse the dynamics of virus persistence in seminal ﬂ uid over time.
Findings We enrolled 26 participants and tested 130 seminal ﬂ uid specimens; median follow up was 197 days 
(IQR 187–209 days) after enrolment, which corresponded to 255 days (228–287) after disease onset. Ebola virus RNA 
was detected in 86 semen specimens from 19 (73%) participants. Median duration of Ebola virus RNA detection was 
158 days after onset (73–181; maximum 407 days at end of follow-up). Mathematical modelling of the quantitative 
time-series data showed a mean clearance rate of Ebola virus RNA from seminal ﬂ uid of –0·58 log units per month, 
although the clearance kinetic varied greatly between participants. Using our biostatistical model, we predict that 50% 
and 90% of male survivors clear Ebola virus RNA from seminal ﬂ uid at 115 days (90% prediction interval 72–160) and 
294 days (212–399) after disease onset, respectively. We also predicted that the number of men positive for Ebola virus 
RNA in aﬀ ected countries would decrease from about 50 in January 2016, to fewer than 1 person by July, 2016. 
Infectious virus was detected in 15 of 26 (58%) specimens tested in mice.
Interpretation Time to clearance of Ebola virus RNA from seminal ﬂ uid varies greatly between individuals and could 
be more than 13 months. Our predictions will assist in decision-making about surveillance and preventive measures 
in EVD outbreaks.
Funding This study was funded by European Union’s Horizon 2020 research and innovation programme, Directorate-
General for International Cooperation and Development of the European Commission, Institut national de la santé et 
de la recherche médicale (INSERM), German Research Foundation (DFG), and Innovative Medicines Initiative 2 
Joint Undertaking.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The Ebola virus disease (EVD) outbreak in west Africa 
lasted more than 2 years, aﬀ ected almost 29 000 people in 
Guinea, Liberia, and Sierra Leone, and resulted in more 
than 11 000 deaths.1 On Jan 14, 2016, WHO declared the 
end of the EVD outbreak in Liberia, with all known chains 
of transmission stopped in west Africa.2 However, there is 
concern about persistence of the Ebola virus in survivors, 
speciﬁ cally in the male reproductive tract.3,4 In conjunction 
with the discovery of ﬁ loviruses in 1967 in Marburg, 
Germany, Marburg virus has been shown to be sexually 
transmitted by men who shed the virus in seminal ﬂ uid 
after recovery from the disease.5 Reports from EVD 
patients subsequently conﬁ rmed virus persistence in 
seminal ﬂ uid after recovery for Ebola and Sudan 
viruses.6–11 A cross-sectional study12 detected Ebola virus 
RNA in seminal ﬂ uid of EVD survivors of the 2014–16 
epidemic up to 9 months after disease onset. However, 
there are no quantitative virus-load data for seminal ﬂ uid 
to facilitate mathematical modelling of virus clearance.
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In this longitudinal study, we measured viral load in 
seminal ﬂ uid from a cohort of men discharged from 
three Ebola treatment units (ETUs) in Guinea between 
January and July, 2015. We aimed to collect sequential 
samples of seminal ﬂ uid every 3–6 weeks from 
participants during follow-up to analyse patterns of 
intensity and duration of Ebola virus shedding in seminal 
ﬂ uid over time.
Methods
Study design and participants
We recruited men aged 18–65 years who had had a PCR-
conﬁ rmed EVD diagnosis, and were discharged from the 
ETUs in Conakry-Gbessia, Forecariah, or Coyah, Guinea, 
between Jan 20, 2015, and July 6, 2015. We contacted 
patients who had been discharged between Jan 20 and 
May 5, 2015, by telephone; and prospectively enrolled 
patients who had been discharged between May 6 and 
July 6, 2015, during their routine 1 month follow-up visit.
We followed up participants at the study centre 
established at the ETU in Coyah. Participants provided a 
sample of seminal ﬂ uid through masturbation in a 
private environment. Follow-up visits were scheduled 
every 3–6 weeks until two consecutive samples were 
negative for Ebola virus RNA on PCR, as recommended 
by WHO.3 We telephoned study participants to remind 
them of follow-up visits 3 days before appointments. At 
enrolment and each follow-up visit, participants were 
counselled about safe sexual practices, and received 
condoms and an expense allowance. The test result was 
communicated by phone to the participants in 
conjunction with safe sex counselling.
We collected clinical and demographic data, including 
date of EVD onset and treatment, from patients’ case 
ﬁ les. Most study participants had received favipiravir on 
a compassionate use basis during the acute illness in 
adherence to the protocol developed for the Jiki trial.13
Participants gave written informed consent and the 
study was approved by the National Committee for Ethics 
in Medical Research of Guinea (permit No. 64/
CNERS/15).
Ebola virus-speciﬁ c real-time RT-PCR
We processed samples of seminal ﬂ uid from participants 
immediately after collection at the European mobile 
laboratory (EMLab) unit in Coyah. Workers extracted 
RNA from 50 μL of seminal ﬂ uid using the QIAamp 
Viral RNA Mini Kit (Qiagen, Hilden, Germany) after 
addition of the internal control RNA for the PCR assay. 
We tested samples for Ebola virus using the RealStar 
Zaire Ebolavirus RT-PCR Kit (altona Diagnostics, 
Hamburg, Germany; this kit is derived from the RealStar 
Research in context
Evidence before this study
Before this study, reports from previous Ebola and Marburg 
virus disease outbreaks indicated that ﬁ loviruses may be 
sexually transmitted by male survivors and that seminal ﬂ uid of 
survivors may contain ﬁ lovirus RNA or infectious particles. We 
did a PubMed search (1960 to March 31, 2015) using the search 
string (ebola virus OR ebola fever OR marburg virus OR marburg 
fever OR ﬁ lovirus) AND (persistent OR persistence OR semen OR 
seminal ﬂ uid OR sexual transmission) [converted by PubMed 
into a longer string with 43 terms] and retrieved 83 citations. 
The search was complemented by gathering information from 
review articles identiﬁ ed through the PubMed search. We 
identiﬁ ed ﬁ ve original articles published between 1968 
and 2007 that were relevant to the design of our study. These 
studies described sexual transmission of Marburg virus in one 
case, and detection of Marburg, Ebola, or Sudan virus or 
corresponding RNA in seminal ﬂ uid of seven of eight male 
survivors (88%) cumulatively tested. The longest time after the 
onset that a semen specimen tested positive was 101 and 
82 days by RT-PCR and virus isolation, respectively. While these 
studies provided proof-of-concept for ﬁ lovirus persistence in 
seminal ﬂ uid, we designed a larger longitudinal study to 
quantitatively describe the dynamics of Ebola virus RNA load in 
seminal ﬂ uid and estimate the parameters of the clearance 
kinetic using mathematical modelling. Before submission of 
this manuscript, we undertook another PubMed search using 
the same terms to consider all evidence that accumulated 
during implementation of our study (April 1, 2015, to 
Feb 21, 2016). The search retrieved 40 citations, of which 
three were relevant to the interpretation of our data. 
One cross-sectional study, which tested one seminal-ﬂ uid 
specimen per survivor, detected Ebola virus RNA in 46 of 
93 specimens (49%). The longest time after the onset that a 
specimen tested positive was 284 days. Two articles described 
one case of sexual transmission of Ebola virus.
Added value of this study
This study provides longitudinal data that allows systematic 
investigation of the dynamics of Ebola virus RNA 
concentrations in seminal ﬂ uid in a cohort of male survivors. 
The quantitative time-series data revealed considerable 
variability between participants in the clearance of Ebola virus 
RNA from seminal ﬂ uid. Although rare, survivors can 
continuously shed Ebola virus RNA for more than 13 months 
after disease onset. We also describe the clearance kinetic as 
well as its variability using biostatistical modelling.
Implications of all the available evidence
The longitudinal data described in this study and cross-sectional 
data are complementary. Biostatistical modelling of these 
datasets facilitates reliable prediction of the proportion of men 
with seminal ﬂ uid positive for Ebola virus RNA over time after 
onset of disease and their prevalence during an epidemic. These 
predictions will assist in decision-making about surveillance and 
preventive measures in Ebola virus disease outbreaks. 
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Filovirus Screen RT-PCR Kit and contains only the 
reagents for detection of Ebola virus) on a Rotor-Gene 
Q thermocycler (Qiagen).14 We included only the runs 
with valid internal control in analysis and we used 
threshold cycle (Ct) as an inverse measure of Ebola virus 
RNA concentration in the specimen. The high precision 
of the kit facilitates pooling of Ct values from separate 
runs for biostatistical analysis (appendix p 1). Relative 
virus RNA concentration (crel, in arbitrary units) was 
estimated from the Ct values using an equation 
(equation 1) based on experimentally generated standard 
curves (appendix p 1).
Remaining specimens were kept on-site at –20°C, sent 
on dry ice by an air courier service to the Bernhard Nocht 
Institute in Hamburg, Germany, and then stored at –80°C 
in the biosafety level (BSL) 4 laboratory. Ct values for 
blood and urine were retrieved from laboratory records.
Factors associated with Ebola virus positivity
In an attempt to identify factors that might be associated 
with Ebola virus detection in seminal ﬂ uid, we used non-
parametric tests to compare participants’ age, time of 
admission after onset, Ct in blood, length of stay in the 
ETU, treatment with favipiravir, and the time after onset 
when the ﬁ rst seminal ﬂ uid sample was taken in 
participants who were negative in all samples and those 
who were positive in at least one sample.
In vitro and in vivo infectivity assay
To show that the Ebola virus RNA detected in seminal 
ﬂ uid was indicative of infectious virus, we selected 
26 samples from eight study participants for infectivity 
testing. We chose participants who had a large number 
of specimens sampled during follow up. Virus infectivity 
assays were done in the BSL-4 laboratory in Germany. We 
used severe combined immunodeﬁ ciency (SCID) mice 
for in vivo testing and had veriﬁ ed that the outbreak 
strain, Ebola virus Makona, eﬃ  ciently replicates in SCID 
mice (appendix p 4). We diluted seminal ﬂ uid by 1:5 in 
SpermRinse (Vitrolife, Göteborg, Sweden) and 
centrifuged at 1500 × g for 2 min. The supernatant was 
cleaned through an Ultrafree-MC HV centrifugal ﬁ lter 
(Merck Millipore, Darmstadt, Germany) at 12 000 × g for 
4 min. We anaesthetised SCID mice with isoﬂ urane and 
inoculated intraperitoneally with 200 μL of cleaned 
seminal ﬂ uid. Two mice were used per seminal ﬂ uid 
specimen. The animals received 1% enroﬂ oxacin in their 
drinking water. We took blood samples from mice once 
per week. At 3–4 weeks from inoculation, mice were 
killed and their organs were collected. We tested blood 
and organs for the presence of Ebola virus RNA using 
the RealStar Zaire Ebolavirus RT-PCR Kit.
To further conﬁ rm the presence of infectious virus, we 
inoculated new SCID mice intraperitoneally with the 
homogenised lung tissue of selected seminal-ﬂ uid-
inoculated SCID mice in 100 μL Glasgow’s minimal 
essential medium (Life Technologies, Darmstadt, 
Germany) supplemented with 2% fetal calf serum. We 
inoculated three mice per sample; one mouse was killed 
at day 2 to generate baseline viral-load data and the 
remaining two were killed at day 30. We tested blood and 
organs for Ebola virus RNA as described elsewhere in the 
Methods. Mouse experimentation was approved by 
Behörde für Gesundheit und Verbraucherschutz, Freie 
und Hansestadt Hamburg, Germany (permit 
V1307/591-00.32).
In addition, Vero E6 and HepG2 cells were inoculated 
with 100 μL cleaned seminal ﬂ uid per well of a six-well 
plate in the presence of vancomycin, gentamicin, 
tetracycline, and amphotericin B. These drugs were 
required because the samples of seminal ﬂ uid were 
heavily contaminated with bacteria and fungi. Cells and 
supernatant were passaged several times. We veriﬁ ed 
virus growth in the cells on immunoﬂ uorescence using 
speciﬁ c antibodies against Ebola virus or an increase in 
virus RNA concentrations in the cell culture supernatant 
of one order of magnitude or more, as measured on real-
time RT-PCR. Before we did the virus isolation 
experiments, we optimised procedures and veriﬁ ed that 
centrifugal ﬁ ltration and the antibiotics and antifungal 
administered did not aﬀ ect Ebola virus titre and growth 
rate in cell culture. Pilot experiments that included 
samples taken early after recovery showed that SCID 
mice are more sensitive than Vero cell culture in 
detecting infectious virus (7/10 vs 1/10 samples tested 
positive; appendix p 5). Therefore, samples from later 
stages (more than 100 days after disease onset) were 
tested in SCID mice only.
Biostatistical modelling
We used a linear mixed-eﬀ ect model to analyse the 
dynamics of virus persistence in seminal ﬂ uid over time 
(appendix p 1). The model had two parameters: a 
hypothetical baseline Ct value at the time of disease onset 
(Ct0), and the clearance rate α. Both parameters were 
assumed to follow a log-normal distribution with a mean 
representing an average patient and a SD for exponential 
individual random eﬀ ects allowing the parameters to 
vary across patients. An error model with errors varying 
proportionally to the predicted Ct was found to best 
describe residual errors. We estimated model parameters 
using the stochastic approximation expectation 
maximisation (SAEM) algorithm in Monolix v4.3 (Lixoft, 
Antony, France).15 This approach is based on maximum-
likelihood estimation, which takes into account the data 
under the limit of detection as left-censored data.16 The Ct 
for negative PCR results was set at >37, which 
approximates the 95% detection limit of our PCR assay.14 
Because the SD for Ct0 in seminal ﬂ uid could not be 
estimated, we used a value of 30%, which corresponded 
to the SD of the Ct values for Ebola virus RNA in plasma 
See Online for appendix
log(crel) = –0·262 × Ct.
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at disease onset (t0). For each parameter, we estimated the 
mean and SD of interindividual variability. The Ct-based 
clearance rate was transformed into an Ebola virus RNA 
clearance rate using equation 1; an increase in Ct by 
3·8 cycles corresponded to a decrease in Ebola virus RNA 
concentration by 1 log unit. To estimate the proportion of 
male survivors with persisting viral RNA, we simulated 
1000 replicate datasets for the 26 study participants using 
the distributions for Ct0 and α and calculated the 
proportion of patients with Ebola virus detectable by PCR 
in seminal ﬂ uid for each day after disease onset (mean 
and 90% prediction interval [PI]). The ﬁ tted decay 
distribution and the previous incidence of EVD in 
Guinea, Liberia, and Sierra Leone from Jan 1, 2014, to 
Oct 14, 2015 were combined to estimate the absolute 
number of men who would still have Ebola virus RNA in 
their seminal ﬂ uid in each week.17 We included conﬁ rmed 
and probable case numbers available from WHO,1 and 
assumed complete reporting, 60% mortality from 
disease, and that 40% of survivors were men.18
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
During the enrolment period, 48 men met eligibility 
criteria, and 39 of these were able to be contacted (81%); 
27 men agreed to participate (56%). One study participant 
was retrospectively excluded because laboratory evidence 
for EVD in this patient was ambiguous. Median age of 
the 26 participants was 31 years (IQR 26–40 years) and 
median Ct value in the diagnostic Ebola virus RT-PCR on 
blood at ETU admission was 28·7 (21·7–30·2). 
Participants had been admitted to an ETU a median of 
4·5 days (IQR 2·2–6 days) after onset of symptoms, and 
were discharged after a median of 12·5 days (IQR 
10–14 days) (table).
Age 
(years)
Acute EVD phase Seminal ﬂ uid samples
Admission to ETU 
(days after onset)
Ct in blood 
at admission
Duration of 
ETU stay 
(days)
Treatment Samples 
(n)
Timing of ﬁ rst 
sample 
(days after onset)
Ct of ﬁ rst 
sample
Last EBOV-RNA 
positive sample 
(days after onset)
Ct of last 
positive 
sample
Last sample 
(days after onset)
Ct of last 
sample
1 40 9 29·4 8 FVP 12 40 23·8 254 31·5 338 -ve
2 45 2 31·5 13 FVP 9 35 28·8 168 36·6 270 -ve
3 35 7 29·2 14 FVP 11 37 25·3 251 33·0 336 -ve
4 18 2 20·0 12 FVP 8 28 24·2 177 34·8 255 -ve
5 33 6 19·9 14 FVP + CP 13 80 27·6 407 35·5 407 35·5
6 26 5 30·1 10 FVP 9 45 25·2 233 39·2 255 -ve
7 30 5 23·0 12 FVP + CP 7 39 22·7 158 33·6 180 -ve
8 46 2 22·0 10 FVP + CP 8 49 28·5 168 30·9 236 -ve
9 19 4 20·0 15 FVP 8 61 29·2 184 29·6 254 -ve
10 28 1 29·7* 9 None 5 85 22·4 177 30·2 282 -ve
11 27 4 20·7 14 FVP 4 47 26·5 57 34·6 243 -ve
12 32 6 25·0 14 FVP 4 85 31·8 94 30·2 274 -ve
13 32 2 17·0 14 FVP + CP 4 63 31·0 72 32·0 268 -ve
14 28 5 19·7 13 None 4 47 35·1 103 36·2 242 -ve
15 40 7 31·6 8 FVP 3 38 26·0 38 26·0 225 -ve
16 35 4 31·7 14 FVP + CP 3 61 33·1 61 33·1 118 -ve
17 18 5 21·8 7 None 2 72 29·2 72 29·2 289 -ve
18 55 7 32·3* 12 FVP + ZMapp 1 73 26·0 73 26·0 73 26·0
19 25 1 21·7 14 FVP 1 95 36·3 95 36·3 95 36·3
20 28 10 29·8 7 FVP 2 48 -ve NA NA 249 -ve
21 15 4 31·5 9 FVP 2 49 -ve NA NA 190 -ve
22 26 4 23·0 14 FVP 2 46 -ve NA NA 241 -ve
23 40 2 38·8 10 FVP 2 98 -ve NA NA 201 -ve
24 18 6 28·3* 13 None 2 91 -ve NA NA 295 -ve
25 47 6 29·6 12 None 2 109 -ve NA NA 314 -ve
26 40 3 30·3 15 None 2 127 -ve NA NA 329 -ve
EVD= Ebola virus disease; EBOV=Ebola virus; ETU=Ebola treatment unit; Ct=threshold cycle of EBOV RT-PCR; FVP=favipiravir; CP=convalescent plasma; NA=not applicable. *Measured after admission (3 days for 
patient 10; 1 day for patient 18; 7 days for patient 24).
Table: Participants’ clinical and demographic data
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Figure 1: Kinetics of Ebola virus RNA clearance from blood, seminal ﬂ uid, and urine
Ct=threshold cycle. Ct value is an inverse measure of the viral load in the body ﬂ uids. Negative PCR results are shown below the dotted horizontal lines drawn around 
the maximum Ct that can technically be measured. For the modelling, the Ct for negative PCR results was set at >37 cycles, which approximates the 95%-detection 
limit of the PCR assay. Patient identiﬁ cation numbers are shown in bold above each plot. Red and blue crosses show positive and negative results, respectively, of 
virus infectivity testing in SCID mice using seminal ﬂ uid samples from patients 1–8. 
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14 patients (54%) had received compassionate 
treatment with favipiravir, ﬁ ve (19%) were treated with 
favipiravir plus convalescent plasma, and one (4%) was 
treated with favipiravir in combination with ZMapp. 
Six participants (23%) had received supportive standard 
of care only.
Collection of seminal ﬂ uid samples began a median of 
55 days (IQR 45–84) after onset of disease. Participants 
were then followed up for a median of 197 days 
(IQR 187–209), which corresponds to a median period of 
255 days (228–287) after disease onset. We collected a 
total of 131 seminal ﬂ uid samples and a valid Ebola virus 
RT-PCR result was obtained from 130 samples; one 
sample was excluded from further analysis because the 
internal assay control failed. Median number of samples 
per patient was 4 (IQR 2–8) (table).
Seminal ﬂ uid from 19 of the 26 participants (73%) was 
positive for Ebola virus on RT-PCR in the initial sample 
(ﬁ gure 1). We analysed 116 samples during follow-up of 
these 19 Ebola-virus-positive participants, of which 86 
samples (74%) tested positive. The last Ebola virus-
positive sample from these 19 participants was taken a 
median of 158 days (IQR 73–181) after disease onset. 
16 of the 19 (84%) participants subsequently cleared 
virus RNA from seminal ﬂ uid. Of the three participants 
with Ebola virus still detectable at the end of the 
observation period, two were lost to follow-up. The 
remaining patient continued to shed Ebola virus RNA in 
seminal ﬂ uid for at least 407 days after onset (patient 5, 
ﬁ gure 1). 21 follow-up samples were taken from all 
patients who had previously tested negative. We did not 
observe re-appearance of Ebola virus RNA in any of 
these samples.
In our analysis of factors that might be associated with 
Ebola virus detection in seminal ﬂ uid, comparing 
participants who were negative in all samples (n=7) and 
those who were positive (n=19) in at least one sample, we 
did not ﬁ nd any statistically signiﬁ cant associations, 
including for treatment with favipiravir, although of note 
is the borderline signiﬁ cance of the time of collection of 
the ﬁ rst sample (median 49 days for Ebola virus-positive 
participants vs 91 days for Ebola virus-negative 
participants, two-tailed p=0·049, Mann-Whitney test).
In our biostatistical modelling, the linear mixed-eﬀ ect 
model ﬁ tted well with the data of the 26 patients 
(appendix p 2). Mean increase in Ct (α) was estimated at 
0·0729 per day of follow-up (SD of the between-
participant variability=0·386), which corresponds to a 
mean decrease of 0·58 log units in the Ebola virus RNA 
concentration in seminal ﬂ uid per month. Using the 
model parameters for the Ct kinetics, we estimated that 
50% of male survivors have PCR-detectable Ebola virus 
RNA in seminal ﬂ uid at 115 days after onset of disease 
(90% prediction interval 72–160) and 10% have detectable 
virus at 294 days (90% PI 212–399) (ﬁ gure 2).
Modelling predicted that at Jan 31, 2016, there would 
have been 16 men (95% CI 2–65) in Guinea, one man 
(0–53) in Liberia, and 27 men (95% CI 1–168) in Sierra 
Leone who had PCR-detectable Ebola virus RNA in 
seminal ﬂ uid (ﬁ gure 3). The mean date by which all men 
should have cleared Ebola virus RNA below the PCR 
detection limit was predicted to be July, 2016, (95% CI 
March, 2016, to April, 2017; deﬁ ned as the ﬁ rst month 
with <1 positive man) in Guinea; February, 2016, 
(October 2015–November, 2016) in Liberia; and 
June, 2016, (February, 2016–March, 2017) in Sierra Leone.
None of the SCID mouse organs collected at day 2 
contained virus RNA, whereas organs of animals 
inoculated with the same inoculum but killed at day 30 
Figure 2: Proportion, over time, of male survivors of Ebola virus disease who shed PCR-detectable Ebola virus 
RNA in seminal ﬂ uid
Data are means and shaded area shows 90% prediction interval [PI].
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contained virus RNA (appendix p 5). Thus, baseline viral 
load in organs is below the detection limit of the RT-PCR 
assay and, so we took the presence of RT-PCR-detectable 
Ebola virus RNA in organs at 3–4 weeks after inoculation 
as evidence of virus replication.
We obtained evidence for infectious virus in 15 (58%) 
of 26 samples from seven of eight participants selected 
for infectivity testing (ﬁ gure 1, patients 1–4 and 6–8). In 
mice inoculated with seven of these samples (Ct range 
22·7–29·9; taken 28–119 days post onset), Ebola virus 
RNA appeared in blood 1–2 weeks post inoculation and 
was detected at the end of the experiment in spleen, 
kidney, liver, lung, heart, and brain (appendix p 4). In 
mice inoculated with the remaining eight samples 
(Ct range 28·5–42·7; taken 49–233 days post onset), virus 
was not detected in blood, but was detected in organs, 
mostly in lung or heart. Inoculation of new SCID mice 
with Ebola virus RNA-positive lung homogenate from 
ﬁ rst-passage mice—including from mice that had had 
virus detected only in the lung—led to appearance of 
virus RNA in blood and presence of virus RNA in organs 
(appendix p 5). The ability to passage the virus further 
conﬁ rms the replication competence of Ebola virus 
detected in the SCID mice.
Discussion
Although earlier studies provided proof-of-concept for 
ﬁ lovirus persistence in seminal ﬂ uid, we designed a 
larger longitudinal study to quantitatively describe the 
dynamics of Ebola virus RNA load in seminal ﬂ uid and 
estimate the parameters of the clearance kinetic using 
mathematical modelling. The ﬁ ndings from our 
longitudinal study not only show the persistence of Ebola 
virus in seminal ﬂ uid, but also describe great variability 
in the duration of Ebola virus RNA shedding in seminal 
ﬂ uid of men who survive EVD. Further, our results of 
infectivity testing in SCID mice showed that Ebola virus 
RNA detected by PCR assay in seminal ﬂ uid is indeed 
indicative of infectious virus particles in a large 
proportion of patients.
Our data set suggests a mean clearance rate of Ebola 
virus RNA from seminal ﬂ uid of about half a log unit per 
month. From cohort data, we predicted that about 10% of 
male survivors still shed Ebola virus RNA above the 
detection limit of our PCR assay almost 10 months after 
disease onset. Our data could be considered in the design 
of post-outbreak surveillance strategies and preventive 
measures to reduce the potential risk of sexual 
transmission of persisting virus.3
The longitudinal setting of our study facilitates 
modelling of the individual virus clearance rate. Indeed, 
we observed a wide variation between participants in 
clearance kinetics. Some men (about a quarter of 
participants in our study) either do not shed virus RNA 
from seminal ﬂ uid at all, or clear the virus from this 
compartment rapidly. However, this proportion might be 
over-represented in our cohort since sampling in men 
who never tested positive was delayed compared with 
men who had at least one positive ﬁ nding (diﬀ erence 
between median times to testing=40 days, p=0·049). 
Nevertheless, our mathematical modelling takes this bias 
into account. All but one man available for follow-up had 
cleared Ebola virus RNA between 50 and 300 days after 
onset. The survivor who did not clear Ebola virus RNA 
remained positive for at least 407 days after disease onset. 
Others, who have also investigated virus persistence in 
the 2014–16 EVD outbreak, have reported the presence of 
virus RNA in seminal ﬂ uid up to 565 days after 
discharge.19,20 Such a long period of virus persistence is 
consistent with our population clearance model.
In agreement with our kinetic model, there were no 
subsequent positive tests from the 21 follow-up 
specimens from patients who had previously tested 
negative, suggesting that clearance is a non-reversible 
process. However, the intervals between sampling were 
too long to detect short-term recurrence. That there was 
no Ebola virus RNA detected in two initial samples taken 
at around day 50 after disease onset (participants 20 
and 21) is consistent with an early study7,8 that reported 
the semen of one of ﬁ ve male survivors as Ebola virus 
PCR-negative at day 62, but contrasts somewhat with a 
2015 cross-sectional study12 that did not observe Ebola 
-virus-negative men within a period of 3 months after 
onset. However, with the exception of this very early 
phase, the ﬁ tted decay distributions describing the 
proportion of men with PCR-positive seminal ﬂ uid over 
time as modelled from our cohort as well as from the 
previous cross-sectional data correspond surprisingly 
well (appendix p 3).17 That longitudinal and cross-
sectional data from two diﬀ erent countries lead to 
essentially the same conclusions is reassuring and 
underlines the validity of the data of both studies.
Most of our patients had been treated with favipiravir 
during the acute phase, in some instances in combination 
with other speciﬁ c therapies. The clinical trial for 
evaluation of favipiravir did not show statistically 
signiﬁ cant eﬀ ects on EVD outcome.13 Consistent with 
this result, we did not note any evidence that favipiravir 
treatment during the acute phase prevents persistence of 
Ebola virus in seminal ﬂ uid. However, our group size 
was not large enough to detect small diﬀ erences with 
statistical signiﬁ cance.
Another potential bias in our study might stem from 
the refusal of about 40% of eligible and reachable 
survivors to participate. We assume that the personal 
nature of the study (for example, the topic of masturbation) 
and its implications for men’s sexual life is a matter of 
concern for potential participants. Men might also fear 
stigma associated with participation within their families 
or communities. However, there is no reason to assume 
that these social and psychological aspects in the selection 
of the participants aﬀ ected the outcome of the study.
The precise body compartment where Ebola virus 
persists and from which the Ebola virus RNA found in 
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seminal ﬂ uid is shed is not known. It might be the testes, 
which is an accepted immunologically privileged site 
where foreign antigens are less well recognised by the 
immune system. However, the prostate gland or other 
accessory glands, which contribute to seminal ﬂ uid, are 
also plausible sites (although not immunologically 
privileged). There are examples of Ebola virus persistence 
in various body compartments; some of them such as the 
placenta,21 eye,22,23  and central nervous system24 are also 
immunologically privileged. However, the detection of 
Ebola virus RNA in saliva,9,25 sweat,26 and breast milk9 may 
point to a certain tropism of the virus to glandular tissue.
Our experiments in mice indicate shedding of 
infectious virus particles in seminal ﬂ uid for up to 
200 days after disease onset (patients 3 and 6), which 
suggests active virus replication at the site of persistence. 
Experimental data are supported by the report20 of a 
probable sexual transmission of the virus from a male 
survivor more than 500 days after onset of disease. The 
clinical relevance of ongoing low-level virus replication 
in the male reproductive tract is unclear. Although we 
have not conducted an in-depth systematic clinical 
investigation at the follow-up visits, none of our study 
participants presented with symptoms that required 
further evaluation.
The relevant operational question arising from this 
study is about the risk of sexual transmission of Ebola 
virus. The data presented here should be interpreted 
with caution. Our models are based on PCR data 
generated with a detection limit of about 3·5 log Ebola 
virus RNA copies/mL and whether this cut-oﬀ  also 
discriminates infectious from non-infectious individuals 
is unclear. We found evidence for infectious virus in 
samples with a wide Ct range, although about 40% of all 
PCR-positive specimens tested negative in SCID mice. 
Thus, PCR-positive samples have to be considered 
potentially infectious; however, we did not establish a 
clear correlation between virus RNA concentration and 
infectivity in our study.
From a technical point of view, the low recovery rate in 
cell culture is worth mentioning. It may be that the 
sample matrix (seminal ﬂ uid) and the speciﬁ c strain had 
a role in this ﬁ nding. The Vero E6 and HepG2 cells we 
used for the experiments might be less permissive for 
Ebola virus Makona in clinical material.
Another limitation of our study is the possible bias in 
selection of the study participants: recruitment was 
mainly from patients who had received drug therapy 
rather than from the larger survivors’ community, which 
may have aﬀ ected the outcome of the study. Further, 
enrolment for some participants was up to 2–3 months 
after disease onset, resulting in fewer data points than 
would be ideal. Therefore, the clearance kinetics might 
be more complex than our linear models predict. To 
identify more complex patterns, future studies should 
sample more frequently, especially at time points closer 
to disease onset. Another study limitation is that given 
the great variability in the clearance kinetics, the 
conﬁ dence intervals for estimates are quite large. There 
is also uncertainty in the assumptions made and, thus, in 
the ﬁ nal predictions of our models. Finally, it remains 
unclear whether survivors with Ebola virus RNA in 
seminal ﬂ uid are generally infectious. Because we could 
not relate virus RNA concentration to infectivity and 
transmissibility, the predictions indicate only the 
potential for sexual transmission of EVD by survivors.
Despite these uncertainties, the data presented here 
might assist in decision-making about post-outbreak 
surveillance and preventive measures. Great care is 
needed in the use of the data to prevent further 
stigmatisation of men who survive EVD.
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